As a powerful phenotyping technology, metabolomics has provided new opportunities in biomarker discovery through metabolome-wide association studies (MWAS) and identification of metabolites having regulatory effect in various biological processes.
Introduction
Large metabolome datasets, generated by metabolomics assays, have become an essential source of information about molecular phenotypes in system biology studies [1] [2] [3] . As an intermediate molecular layer between genes and disease phenotypes, metabolite levels and the corresponding pattern of changes are highly associated with the degree of perturbation in biological systems and rewired metabolic networks in a given phenotype .
Liquid chromatography-mass spectrometry (LC-MS) has become the most widely used experimental platform in the study of the metabolome, owing to the progressive improvement of the instrumental conditions in terms of sensitivity and selectivity 13 .
However, LC-MS based metabolomics assays suffer from the inherent variation in the distribution of signal measurements and/or in the signal sensitivity and intensity driven by external factors 13 . This signal drift remains a major limitation to data normalization in biomedical and clinical studies, adding up to the biological inter-individual variability and unavoidable technical variation introduced during sample preparation 14 . In particular, such drift can significantly compromise the technical precision and signal stability in large-scale studies, where the data acquisition for several hundred to thousands of biological samples needs to be done in different analytical blocks (i.e. batches) over several weeks or even months 14, 15 . In this case the largest variance in the dataset may be assigned to the batch effect or experimental run order, thus hindering the real biological difference and true functional signals, leading to data misinterpretation 14, 16, 17 . Therefore, prior to any chemometrics analysis, large metabolomic datasets need to be corrected for the unwanted analytical, within-and between-batch variation, in order to make data comparable and reveal biologically relevant changes 18 .
In most of the LC-MS-based metabolomics data processing workflows, signal intensity drift correction is performed using quality control (QC) samples per metabolite feature.
QC samples are aliquots of a QC pool, representative of entire sample set. QC samples are injected within each batch periodically (every 4-10 samples) to monitor signal drift over time and evaluate the system performance and data quality [19] [20] [21] . However, in largescale studies, the preparation of such QC samples may be difficult due to large number of samples, whose handling would involve additional freeze-thaw cycles. Moreover, one may want to start the data acquisition before finalizing the sample collection. In such cases, surrogate QC samples are required 19, [22] [23] [24] [25] . In general, the drift correction using QCs is based on the assumption that the same sources of variation apply to the metabolites present in both biological samples and QCs, as their representative pools.
In a majority of QC-based workflow, an equalization step is considered for batch-effect correction to remove signal intensity drift via several commonly proposed algorithms, such as batch-ratio-based correction 26 , regression-based models 19, 26, 27 and/or linear and non-linear smoothing algorithms (e.g. lowess-model ) 19, [27] [28] [29] [30] . Beyond the algorithmspecific assumptions, the fundamental premise of all QC-based correction models is that QCs and study samples contain the same metabolite features 23, 27 , a condition that might not be met when using surrogate QC sample. In this case, the features that are detected in the subject of study, but are missing in the QCs, must be excluded before the application of a QC-based correction model. This limitation leads to loss of information in the metabolic phenotyping and may bias new discoveries 19, 31, 32 .
Another implemented solution for correcting signal drift in the analytical measurements via LC-MS-based metabolomics is spiking stable isotope-labeled metabolites into samples prior to metabolite extraction. This procedure is supposed to control both signal fluctuation during cross-comparison of different batches and biases introduced during sample preparation 33, 34 . However, metabolome size and diversity are too high to be completely covered by corresponding internal standards 35 , and signal variability for internal control metabolites may not truly reflect that of other endogenous or /and exogenous compounds, due to the difference in their chemical properties 25, 36 . Hence, this method should not be favored for the correction of potential batch effects in metabolomics assays 37 .
Alternatively, using models and algorithms that are not dependent on QCs might be a genuine and alternative way to compensate for technical sources of variation in a largescale/ long-run study. In particular, there has been a growing interest in adopting and applying specific statistical methods that were originally developed for microarray based gene expression data to adjust for unwanted variation in metabolomics data. Such methods include removal of unwanted variation (RUV) model [38] [39] [40] , linear model for microarray data (LIMMA) 36, 41 , and ComBat using empirical Bayes methods (EB) 17, [42] [43] [44] 45 .
While these models can successfully correct for unwanted variation, they rely on a set of assumptions limiting their application to metabolomics data. For example, on one hand RUV model depends on prior knowledge of metabolome features (variables) detected in the study groups, because it settles the analytical variation based on the behavior of negative control features, whose levels are supposed to remain constant in different biological conditions 36, 39 . On the other hand, LIMMA model strictly dependent on some additional information on sample metadata such as biological covariates, which are used for the design of the model matrix 41 . In contrast, ComBat has the flexibility to adjust batch effect by integrating information on both batches and biological covariates or just on batches if demography of population is not available 9, 14 . This function is developed in the global term of "Parametric shrinkage adjustment" and accommodates batch effect in three steps: data standardization, batch effect estimation via empirical priors and batch effect removal using the adjusted estimators 45 . Although making strong parametric estimation, ComBat has been recognized for its superior performance in adjustment of unwanted variation compared to several others models 42 . ber is another statistical model that was developed for batch effect correction in gene expression data.
It is based on a two-stage regression procedure and uses linear fitting for both location and scale (L/S) parameters 46 . Interestingly, this model showed a better performance in microarray data compared to the empirical Bayes model implemented in ber, but was never tested for metabolomics data 46 .
Herein, we describe "dbnorm", a new package in R environment, which incorporates a collection of functions applicable to large-scale metabolomics datasets for data visualization and for normalization cross batches.
Results

Statistical modeling for intra-and inter-batch signal drift correction in large-scale metabolomics datasets
Despite their efficiency in removing intra-and inter-batch signal drift, the application of QC-based approaches might be limited by the impossibility to have QC samples highly representative of the whole sample set, particularly in large-scale population studies. To overcome this issue, statistical models that were originally developed for microarray gene expression data can be used to address the unwanted variation (e.g. batch effect) in metabolomics data. These statistical models offer the flexibility to accommodate signal variation across multiple batches based only on the sequence of acquisition, or integrating also other available population demographic characteristics (i.e. treatment) 9, 14 , which is recommended in case of uneven study design.
We developed a new R package "dbnorm" in which, besides several functions for preprocessing of data and estimation of missing values, we assembled two distinct functions for batch effect correction based on statistical models: ComBat (both parametric and nonparametric), that was already in use for metabolomics data normalization, and ber, that we propose here as an additional tool for drift adjustment across multiple batches in metabolomics datasets. The performance of these two statistical models was assessed on two different big metabolomics datasets, using traditional QC-based methods (ie. lowess -model) as a reference for result comparison. Of note, for each analyzed dataset, "dbnorm" generates diagnosis plots and calculates a score value which helps users to easily choose the statistical correction model which best fits their data structure. The statistical models and the underlying algorithms are explained in the method section. 
Drift correction in a large-scale targeted metabolomics dataset from a human prospective cohort study
The first dataset employed to test "dbnorm" is a set of targeted metabolites from plasma samples of 1,079 individuals, analyzed in 11 analytical batches over a period of 12 months, and yielding data on 239 metabolites detected across all samples (see method section).
Across-batch drift assessment
As previously described, in the majority of large-scale metabolomics experiments, QCs are periodically analyzed throughout an analytical run to allow for signal drift and data quality assessment. Therefore, distribution of QC signal is indicative of amplitude of analytical variation in the analyzed dataset. To perform the QC-based drift correction on the above specified dataset acquired on human cohort, we retrieved the data for 135
QCs injected periodically, every 10 samples. Unsupervised principal component analysis (PCA) of acquired individual metabolic signatures, including 239 detected metabolites, revealed a clear distinction between QC sets analyzed in different batches or experimental runs ( Fig.1A) , with the first two principal components (PCs) explaining 65% of the variance mainly derived from batch effect or analytical variability (Supplementary Figure 1A ).
Importantly, total ion current (TIC) in the QCs showed a 10-fold signal intensity drift across batches, with a gradual signal decrease from 1.3 10 7 ion counts in batch 1 to 5 10 6 ion counts in batch 11 (Supplementary Figure 2 ). Consistently with that, the relative log abundance (RLA) plot showed a moderate drift in the total centered median ion intensity across the experimental runs ( Figure 1C ). Moreover, multivariate unsupervised hierarchical clustering analysis (HCA) confirmed the sample clustering per batch, as depicted in Figure 1E . To correct for within and between batch effects and normalize the data prior to statistical analysis, we applied the statistical models implemented in Following the data quality assessment using QCs, we performed explorative statistical analysis of biological samples comprising the analyzed individuals, prior to and following the drift correction. PCA plot of raw data (i.e. prior to drift correction) generated in both positive and negative ionization modes showed sample clustering by batch order ( Figure   2A ). In addition, probability density function plots (PDF plots) of metabolite distribution across batches showed shifted PDFs for the majority of metabolites detected in the study samples (see example of 3-Hydroxy-3-methylglutarate and 2',3'-cyclic phosphate 3'-CMP in Supplementary Figure 4A and B). In parallel, Adjusted-Coefficient of Determination (Adj. R. squared) revealed the high dependency between variability in the dataset and across-batch signal drift, with > 50% of variability explained by batch for most metabolites ( Figure 2D and Supplementary Table 1 ).
We thus employed the three available statistical models implemented in the "dbnorm" R package (ber, parametric and non-parametric ComBat) to accommodate the signal drift observed in the whole dataset. To evaluate their efficiency to correct the signal drift within-and between-batches, we compared them to reference QC-based models, such as lowess. In general, the spatial separation predictive of batch effect was significantly Although the QC-based lowess model considerably reduced the batch-associated signal variability, as indicated by the decrease of the Adj. R. squared value compared to raw data ( Figure 2E ), the signal intensity for some metabolites was still strongly associated with the injection order over time estimated by regression model (Figure 2E , Supplementary Table 2 ). As an example, the clear batch-dependent shift in the signal intensity of citrate that was observed in the raw data, was preserved for some batches in the lowess-corrected data (Supplementary Figure 5A Depending on proportion of variability explained by the batch, the "dbnorm" tool will calculate a score for the maximum variability defined in each model to facilitate the conclusion about the model which provides the best compromise for drift correction considering the consistency of overall model performance for all detected metabolites.
As shown in Supplementary Figure 7 and Supplementary 
Treatment of batch effects improves downstream differential analysis
To investigate to which extent the quality of data might affect the data interpretation in this study, we next explored the impact of each type of correction algorithms on the downstream statistical and metabolic pathway analysis.
All the subjects of this prospective cohort study were previously phenotyped for kidney functionality and associated parameters, such as age, sex, and creatinine clearance, as an indicator of renal impairment to estimate the severity of a kidney disease 47 . In addition, Glomerular Filtration Rate (GFR), a major surrogate of kidney function, is measured on a continuous scale and estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) 48, 49 (Methods). We thus took advantage of this information to have further indication on the performance of the different statistical models employed for data correction. We first evaluated the correlation between creatinine levels, determined by the targeted LC-MS/MS metabolomics experiment with that of measured.
We looked at 5 datasets: raw data, lowess-corrected, ber-corrected and parametric-and nonparametric-ComBat -corrected. All applied normalization models improved the correlation between creatinine levels measured routinely with an enzymatic assay and those obtained using targeted LC-MS/MS analysis. The correlation coefficient (r) passed from 0.18 observed in raw MS data, to 0.5 in the lowess-corrected data and up to 0.6 for the data corrected by statistical models (Figure 3A) . Using a multiple regression model, we found that the expected significant correlation between the outcome of renal failure such as CKD-epi and creatinine (predictor) revealed only when data are corrected for batch effect through either QC-based or statistical-based models, as shown by the increased absolute regression coefficients and decreased p-value in both lowess-and bercorrected data ( Figure 3B ). Likewise, other metabolites that are known to be associated to renal failure such as gluconate, citrulline, and hippurate 47 , showed a significant association to CKD-epi level only in the lowess-or ber-adjusted data (data not shown). Unsupervised multivariate analysis of these metabolic profiles (i.e. PCA and HCA)
supported the presence of a strong batch effect, with samples clustered in the corresponding analytical batches ( Figure 4A ). In addition, the adjusted coefficient of variation estimated by regression model indicated that the variability of certain metabolites can be entirely explained by the signal intensity drift between batches (Supplementary Figure 8B) . Following the signal drift correction using statistical models, the batch effect was removed, as suggested by the PCA scores plot and HCA dendrogram ( Figure 4B and D, Supplementary Figure 8A) . The high variability observed in the raw 
Batch effect correction facilitates the discovery of biologically relevant changes
We finally investigated the importance of data correction for unwanted variation in a large-scale untargeted metabolomics assay with the aim of capturing true biological differences due to treatment in our case study. To this end, we compared the candidate list obtained from statistical analysis of raw data to that resulting from normalized data following the batch correction using the statistical models ber, parametric and nonparametric ComBat, implemented in the "dbnorm" tool. While the majority of the significant changes were detected in all analyzed datasets, the list of candidate metabolites associated with the HFD treatment was more exhaustive after adjustment ( Figure 4E ). As depicted in the volcano plot ( Figure 4F ), the levels of several metabolite features (variables) were revealed as significantly different only after batch effect removal, thus suggesting that in the raw dataset some biological signals induced by HFD might be overlooked due to high analytical variability. Accordingly, the data interpretation using metabolite set enrichment analysis (MSEA) varied between raw and normalized datasets. For instance, several biological pathways including "Fatty acid biosynthesis", "Retrograde endocannabinoid signaling" and "Biosynthesis of unsaturated fatty acids", "Linoleic acid metabolism ", that were previously shown to be influenced by HFD in adipose tissue [50] [51] [52] , were enriched only using the list of candidates as a result of statistical analysis of normalized datasets ( Figure 4G ). No significant difference was observed depending on the statistical model applied thus cross-validating the performance in drift correction. methods. For instance, we show that in the human dataset that we analyze, citrate levels remain highly associated to the batch order in the lowess-adjusted data, which might generate bias in data interpretation. On top of that, the analysis with a QC-based correction model is restricted only to the metabolites that are detected in both QC and study samples, thus potentially impairing the discovery of novel biological hits in a medical condition. In our dataset, xanthosine 5'-monophosphate is only detected in the study samples, but not in QCs, and is therefore discarded a priori by the lowess-model.
In our human population dataset, while variability linked to batch is still present for some metabolites by using QC-based lowess correction model, all the statistical models implemented in the "dbnorm" package, present a higher performance on the overall correction of signal drift across batches, with parametric ComBat and ber showing the best score. However, we cannot exclude that other datasets, with a different data structure, might be more effectively adjusted by non parametric ComBat and QC-based models.
Our results clearly demonstrate the substantive impact of data adjustment for analytical heterogeneity on the prediction of clinical outcomes. In the human study, data normalization triggered an increased association between eGFR (the outcome measured via the CKD-epi formula) and creatinine, thus highlighting a pattern that was not detected in raw data. This also indicates that data correction performed on our dataset is not overfitting the data, but rather favoring the detection of biologically relevant differences. Knowing that ComBat-model is developed to avoid overfitting of the data in case of small sample set in each batch, we found computational advantages using the ber-model, thanks to higher speed in processing the metabolomic data.
Similarly, in our mouse experiment, the statistical models compensating for across batch signal drift drastically decreased the high variability associated to batch level in the raw dataset to the almost zero level in the corrected datasets, with a more consistent removal observed when employing parametric ComBat-model and ber-model. Data correction and automation resulted in a slightly distinct list of differential features associated with HFD-treatment, with similar candidates given by ber-, parametric-ComBat and non-parametric-ComBat models. Although the list generated by using raw data lacked only few metabolite candidates, this small difference impaired the enrichment of a series of biological pathways that are known to be affected by HFD treatment 46, 48, 49 , thus reducing the biological significance of the results.
In conclusion, in agreement with previous reports, our study supports the necessity of data cleaning from unwanted technical variation, which helps improving the detection of biological mechanisms underlying a treatment or medical state. "dbnorm" is an efficient and user-friendly tool for removal of drift across batches. It helps users to diagnose the presence of analytical drift thanks to several visual inspections based on advanced statistical inferences implemented in the package. In addition, different statistical models are implemented, namely ComBat-and ber-. In addition, several functions implemented in the "dbnorm" assist users to visualize the structure of large datasets after correction via the implemented methods, distinctively from the perspective of samples analyzed in the entire experiments and the features detected in the study samples. Notably, "dbnorm" and its application is not limited to the metabolomics data, but could be extended to other high-throughput techniques. In which is expression value for gene g for sample j from batch i, ̂ is the overall gene expression, X is a design matrix for sample conditions, and ̂ is the vector of regression coefficients corresponding to X and estimated variance of ̂.
Methods
In contrast, ber-function uses linear regression at two stages to estimate location and /or scales parameters:
In which Bb which is × matrix for batch l= 1,…,mb and gene in j = 1,…,g is estimated by first regression model where E is a matrix of error. The second regression is applied on the squared residual of the first stage, ̂2 . ̂ is the estimated matrix parameter for the scale batch. Upon calculation of its mean denoted by ̂2 = ( 1 ) ∑̂2 =1 for gene j, data are transformed to calculate and remove batch effect.
Human prospective cohort study SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is a family-based multicenter population-based study exploring the role of genes and kidney haemodynamics in blood pressure (BP) regulation and kidney function. Method and population are described in details elsewhere [53] [54] [55] .
Animal experimentation
All animal experiments and procedures were approved by the Swiss Veterinary Office (VD-2942.b. and VD-3378). C57/BL6 male mice were purchased from Janvier Labs and housed 5 per cage in the animal facility of Centre for Integrative Genomics, University of Lausanne.
Four-week old mice were fed for two weeks with a 10% in fat chow diet (D12450J, Research Diet). At 6 weeks of age they were either shifted to a high-fat diet (HFD) containing 60% fat (D12492, Research Diet) or kept on a control diet for 1 or 8 weeks.
Random blocking was used. Efficiency of the diet-induced obesity was followed by regular measurements of weight 56 . All animals were kept in a 12:12 h light:dark cycle with water and food ad libitum. All the mice were sacrificed by CO2 between ZT2 and ZT5. In this study sc-AT refers to inguinal subcutaneous adipose tissue in mice.
Metabolomics
Targeted metabolomics analysis conducted on the plasma samples of the human prospective cohort study study. Metabolites were extracted from 100 µL plasma samples using a methanol-ethanol solvent mixture in a 1:1 ratio. After protein precipitation, To obtain the fat metabolome profile in the mice, metabolites were extracted from 10-20 mg of fat depots either sc-AT or v-AT using 400 µL of mix organic solvent comprising EtOH: MeOH: H2O in the proportion of 2:2:1 to remove protein efficiently as well as to extract polar and semi-polar metabolites successfully. All the samples were then vortexed mixed for 30 s, incubated for 10 min at 4°C and centrifuged for 10 min at 14,000 rpm and 4 °C. The supernatants were removed and evaporated to dryness using speed vacuum concentrator (SpeedVac) and stored at -80°C until analysis. QCs were prepared by pooling all the tissue integrated in the study. Extraction was done using similar protocol use for the samples. Supernatant were aliquots in 34 tubes considering similar quantity. Then they were treated like samples.
Untargeted metabolomics approach applied in this study has been described in our 
Chemometrics and Pathway analysis
For analysis, raw data generated in targeted metabolomics were log2-transformed for each metabolite. Further normalization for across-batch signal drift was don using either QC-based model specifically lowess-model from open access web page (http://prime.psc.riken.jp/Metabolomics_Software/LOWESS-Normalization/) or non-QC based algorithms using "dbnorm" package. Notably, data for each mode of acquisition was treated separately for batch effect removal through either of QC-based or non QCbased model, and then merged for visual check and downstream differential analysis.
A total of 239 different plasma metabolites detected in a human prospective cohort study study among which XANTHOSINE 5'-MONOPHOSPHATE was missing in QCs analyzed in positive modes.
Untargeted metabolomics data subjected to batch effect was also treated for normalization of across-batch signal drift using statistical methods implemented in the "dbnorm" package, which is also used for visualization of the outcome.
Metabolome signature in either of study, human study and animal experiment, was obtained by linear logistic regression model using lm ( https://www.rdocumentation.org/packages/stats/versions/3.6.1/topics/lm ) and limma package (), respectively. In the study of SKIPOGH-prospective cohort study, GFR is estimated by an equation developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and used as an outcome of renal impairment , and its association with plasma metabolome is investigated by multiple regression testing adjusted for age and sex.
In mouse model of obesity, we mainly focused on sc-AT metabolome signature driven by HFD after 8 weeks treatment, in comparison with their Ctrl counterpart. Subsequently, significant list was further searched and filtered against a Human Metabolome Database (HMDB; http://www.hmdb.ca) to keep only potential hits that were ultimately confirmed by MS2 spectra. Differential list in either of project, human prospective cohort study or animal experiment, was then subjected for over-representation analysis (ORA) using web interface of ConsensusPathDB ( http://consensuspathdb.org ) to pinpoint biochemical pathways that are dysregulated and may have a causative relationship to the phenotype.
The list of identifiers was mapped to predefined KEGG pathways database enlisted by 4289 compound IDs. "p-value is calculated according to the hypergeometric test based on the number of physical entities present in both the predefined set and user-specified list of physical entities" (http://cpdb.molgen.mpg.de/ ). The selection criteria was that at least two metabolites representing the biological pathways displayed a significance level < 5% (q-value <0.05). Pathway visualization was done by BioCircos package (https://cran.r-project.org/web/packages/BioCircos ).
